Information from Glaxo Wellcome's trials of BioChem Pharma Inc.'s Epivir/HBV for hepatitis B virus could change the way clinicians think about analyzing the condition of patients and the way clinical trials in the disease are designed.

At last week's FDA Antiviral Drugs Advisory Committee review of Epivir/HBV, panel members decided to place a greater emphasis on the interpretation of liver biopsies than on